XNCR

Xencor, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$38.13

Price (1 Year)

$38.13 $11.22

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %8.4 / %30
Non-compliant assets / Total market cap %48.9 / %30
Non-compliant revenue / Total income %8.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Website

Analysis (Turkish): XNCR Hissesi Caiz mi, Helal mi? Xencor, Inc. Katılım Analizi